Relationship of serum beta‐synuclein with blood biomarkers and brain atrophy
Authors:
Open Access
- 21 September 2022
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (4) , 1358-1371
Abstract
Background: Recent data support beta‐synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD).Methods: We provide a detailed comparison of serum beta‐synuclein immunoprecipitation – mass spectrometry (IP‐MS) with the established blood markers phosphorylated tau 181 (p‐tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores.Results: Serum beta‐synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta‐synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p‐tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy.Discussion: Serum beta‐synuclein changes differ from those of NfL and p‐tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta‐synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations.Highlights: Blood beta‐synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta‐synuclein correlates with temporal brain atrophy in AD. Blood beta‐synuclein correlates with cognitive impairment in AD. The pattern of blood beta‐synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p‐tau181) and neurofilament light (NfL).Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (EXC2145SyNergy–ID390857198)
This publication has 20 references indexed in Scilit:
- Meta‐analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerabilityAlzheimer's & Dementia, 2016
- C‐terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's diseaseAlzheimer's & Dementia, 2015
- Criteria for the diagnosis of corticobasal degenerationNeurology, 2013
- Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementiaBrain, 2011
- Classification of primary progressive aphasia and its variantsNeurology, 2011
- Validation of the New Interpretive Guidelines for the Clinical Dementia Rating Scale Sum of Boxes Score in the National Alzheimer's Coordinating Center DatabaseArchives of Neurology, 2010
- Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structuresNeuroImage, 2010
- Construction of a 3D probabilistic atlas of human cortical structuresNeuroImage, 2008
- Phases of Aβ-deposition in the human brain and its relevance for the development of ADNeurology, 2002
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)Neurology, 1996